Safety and clinical activity of autologous RNA chimeric antigen receptor T-cell therapy in myasthenia gravis
Myasthenia gravis (MG) is a prototypical neuroimmunological disorder in which autoantibodies targeting the neuromuscular junction play a key role in the pathogenesis. Granit et Al. reported the results of a prospective, multicenter, open-label, phase 1b/2a study that investigated the safety and efficacy of Descartes-08, a chimeric B-cell antigen receptor anti-maturating antigen (BCMA) T-cell therapy, in […]